MedTrace Logo

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

NCT00419952 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 742

Last updated 2012-10-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.

Conditions

Interventions

DRUG

Budesonide/formoterol (SYMBICORT) pMDI

Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)

DRUG

Budesonide HFA pMDI

Budesonide HFA pMDI 160 ug x 2 actuations BID

Sponsors & Collaborators

Principal Investigators

  • Christer Hultquist, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419952 on ClinicalTrials.gov